Introduction
============

*Acinetobacter baumannii* is an important opportunistic pathogen that causes various types of human infections and has become a primary cause of nosocomial infections because of its broad antimicrobial resistance ([@b1-etm-0-0-3828]--[@b3-etm-0-0-3828]). Aminoglycosides, a type of broad-spectrum antibiotics, continue to serve an important role in treating serious infections caused by gram-negative bacteria ([@b4-etm-0-0-3828]). However, aminoglycoside resistance of *A. baumannii* has rapidly increased and given rise to more challenges in the clinical treatment of infections ([@b5-etm-0-0-3828]).

*A. baumannii* shows resistance to aminoglycosides since functional aminoglycosides can be modified by various aminoglycoside-modifying enzymes, including acetyltransferases, phosphotransferases and nucleotidyltransferases, into non-functional forms in the bacteria ([@b6-etm-0-0-3828]). In addition, aminoglycoside antibiotics bind specifically to the A-site of 16S ribosomal (r)RNA in the 30S small subunit and interfere with the decoding of mRNA to inhibit protein synthesis ([@b7-etm-0-0-3828]). In addition, at least ten 16S rRNA methylase genes (*armA*, *rmtA, rmtB, rmtC, rmtD, rmtE, rmtF, rmtG, rmtH* and *npmA*) have been identified ([@b8-etm-0-0-3828]--[@b12-etm-0-0-3828]). These 16S rRNA methylases, which lead to the high-level resistance of various aminoglycosides, can easily transfer to other bacteria since their genes are typically present on plasmids ([@b13-etm-0-0-3828]). Therefore, the emergence and spread of such bacteria should be carefully monitored. Since the 16S rRNA methylases are key factors in the aminoglycoside resistance of *A. baumannii*, the investigation of the acquisition of 16S rRNA methylase genes by clinical isolates is important for the prevention and treatment of their infections ([@b14-etm-0-0-3828]).

Aminoglycosides and carbapenems represent the class of antimicrobials that are used to treat *A. baumannii* infections. Aminoglycoside antibiotics are frequently ineffective against strains of *A. baumannii*; however, combinations of aminoglycosides and carbapenems can produce synergistic effects to treat infected patients ([@b15-etm-0-0-3828],[@b16-etm-0-0-3828]). Previously, it has become evident that the outgrowth of carbapenem-resistant isolates has resulted in it being difficult to treat *A. baumannii* infections. One of the most important mechanisms underlying the resistance of carbapenems is the production of carbapenemases in *A. baumannii* ([@b17-etm-0-0-3828]). Class D oxacillinases (OXA type) are the primary cause of prevalence in *A. baumannii* strains ([@b18-etm-0-0-3828]). In addition, causes stem from class B β-lactamases (metallo-β-lactamases) and *Klebsiella pneumoniae* Carbapenemase (KPC) producers. These carbapenemases are a diverse group of β-lactamases that are active against the carbapenems, resulting in their limited clinical use.

Several studies have documented the co-existence of *bla*~OXA-23~ and *armA* in multidrug resistant *A. baumannii* isolates ([@b19-etm-0-0-3828]--[@b22-etm-0-0-3828]). For example, Doi *et al* ([@b19-etm-0-0-3828]) first discovered that two of five *A. baumannii* isolates coproduced OXA-23 β-lactamase and ArmA in North America in 2007. In addition, further cases were reported in Korea ([@b20-etm-0-0-3828],[@b23-etm-0-0-3828]), India ([@b24-etm-0-0-3828]), France ([@b25-etm-0-0-3828]), Bulgaria ([@b26-etm-0-0-3828]), Italy ([@b27-etm-0-0-3828]), Latvia ([@b28-etm-0-0-3828]), East Africa ([@b29-etm-0-0-3828]), Yemen ([@b30-etm-0-0-3828]), Japan ([@b31-etm-0-0-3828]), Brunei ([@b32-etm-0-0-3828]), Egypt ([@b33-etm-0-0-3828]) and China ([@b21-etm-0-0-3828],[@b34-etm-0-0-3828],[@b35-etm-0-0-3828]). The authors of the present study previously determined that extended-spectrum β-lactamase and 16S rRNA methylase are coproduced in *A. baumannii* ([@b36-etm-0-0-3828]). However, the high-level resistance to aminoglycosides, coupled with carbapenem resistance in *A. baumannii*, were not reported over the 4-year period in China, particularly in western China.

The aim of the present study was to explore the high-level resistance mechanisms against aminoglycosides, and to investigate the presence of carbapenemases among strains of *A. baumannii*. In addition, the relatedness of aminoglycoside- and carbapenem-resistant strains, determined through epidemiologic examination, is described. To the best of our knowledge, the present study is the first to document the emergence of *A. baumannii* producing *bla*~OXA-23~ and *bla*~OXA-51~ carbapenemase-encoding genes among *armA* 16S rRNA methylases at a university hospital in western China. Furthermore, the results aim to emphasize that the dearth of appropriate treatments remains a primary concern regarding multidrug-resistant infections.

Materials and methods
=====================

### Clinical isolates

A total of 118 strains of *A. baumannii* were consecutively collected in a university hospital of western China between February 2012 and July 2013. Rapid species identification was performed by polymerase chain reaction (PCR), as reported within 'Resistance gene amplification' and previously described ([@b37-etm-0-0-3828]). *A. baumannii* was identified and confirmed if the following two PCR products were yielded: A 425-bp internal control amplicon corresponding to the *recA* gene of *Acinetobacter spp*., and a 208-bp fragment of the 16S rRNA intergenic spacer region of *A. baumannii* ([@b38-etm-0-0-3828]). Non-*baumannii* species of *Acinetobacter*, which yielded the 425-bp product alone, were excluded in this study. Isolates were obtained from specimens including sputum, secretion, lavage fluids, blood and other specimens. All strains were stored at −80°C. Bacteria were grown on tryptose agar or Mueller-Hinton broth. No amplicons were obtained with bacteria belonging to other genera.

### Antimicrobial susceptibility testing

The minimum inhibitory concentrations (MICs) of amikacin and gentamicin (Sangon Biotech Co., Ltd., Shanghai, China) for *A. baumannii* were determined on Mueller-Hinton agar plates by agar dilution according to the protocol recommended by the Clinical and Laboratory Standards Institute ([@b39-etm-0-0-3828]). MICs of meropenem and imipenem (Sangon Biotech Co., Ltd.) were tested in high-level aminoglycoside-resistant isolates. The results were interpreted according to the CLSI guidelines. *Escherichia coli* \[American Type Culture Collection (ATCC) 25922\] and *A. baumannii* (ATCC 19606) (ATCC, Manassas, VA, USA) were used as quality control strains.

### Resistance gene amplification

The aminoglycoside-modifying enzyme genes and the 16S rRNA methylase genes were detected by PCR. Total DNA was extracted by boiling at 95°C for 15 min. After centrifugation at 13,000 × *g* for 10 min to pellet the debris, the supernatant was stored at −20°C for further assays. PCR was performed in a total volume of 50 µl containing 0.2 mM of each deoxynucleotide, 0.5 µM of each primer ([Table I](#tI-etm-0-0-3828){ref-type="table"}), 2.5 units *Taq* polymerase (Takara Bio, Inc., Dalian, China) and 5 µl 10X buffer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Primers listed in [Table I](#tI-etm-0-0-3828){ref-type="table"} were synthesized by Sangon Biotech Co., Ltd.. The PCR thermal cycling conditions were as follows: Initial denaturation at 94°C for 5 min in order to obtain partial activation of *Taq* polymerase; then, the number of cycles was increased to 30, each consisting of a denaturation step for 30 sec (at 94°C), an annealing step for 30 sec (at 55°C for *armA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtE*, *rmtF*, *rmtG*, *rmtH* and *npmA*, at 53°C for *ant(2″)-Ia*, *aph(3′)-1a*, *aac([@b3-etm-0-0-3828])-Ia* and *aac([@b3-etm-0-0-3828])-IIa*, and at 56°C for *aac(6′)-Ib*) and an extension step for 30 sec (at 72°C). Each amplification experiment included a blank containing the reagent except for target DNA. The products were electrophoresed in 1% agarose gels and visualized under ultra-violet light (Bio-Rad Laboratories, Inc., Hercules, CA, USA). All *aac(6′)-Ib* PCR products were directly sequenced and compared with the published nucleotide (NC_005327.1).

Genes coding for classes A, B and D carbapenemases were investigated among high-level aminoglycoside-resistant isolates by PCR. The genes encoding class A, such as *Klebsiella pneumoniae* carbapenemase gene (*bla*~KPC~) ([@b40-etm-0-0-3828]), class B, such as the metallo-β-lactamase genes \[*bla*~IMP~ ([@b41-etm-0-0-3828]), *bla*~VIM-1~ ([@b42-etm-0-0-3828]), *bla*~SIM~ ([@b43-etm-0-0-3828]) and *bla*~NDM-1~ ([@b44-etm-0-0-3828])\] and class D, such as CHDLs \[*bla*~OXA-23~ ([@b45-etm-0-0-3828]), *bla*~OXA-24~ ([@b45-etm-0-0-3828]), *bla*~OXA-51~ ([@b46-etm-0-0-3828]) and *bla*~OXA-58~ ([@b47-etm-0-0-3828])\], were also analyzed using PCR. Reaction conditions of PCR were as follows: 94°C for 5 min; and 30 cycles of 94°C for 30 sec, 56°C for 30 sec and 72°C for 30 sec; followed by a final extension at 72°C for 5 min.

### Multilocus sequence typing (MLST)

MLST was performed according a the previously described *A. baumannii* MLST study ([@b48-etm-0-0-3828]). Briefly, internal fragments of seven housekeeping genes (*gltA*, *gyrB*, *gdhB*, *recA*, *cpn60*, *gpi* and *rpoD*) were amplified by PCR ([@b49-etm-0-0-3828]). The sequences of the seven housekeeping genes were compared with existing sequences in the MLST database ([@b50-etm-0-0-3828]) for the assignment of allelic numbers. Sequence types (STs) were assigned according to their allelic profiles. New allele sequences and STs were assigned in accordance with the PubMLST database ([@b50-etm-0-0-3828]). The eBURST program (<http://eburst.mlst.net>) was used to cluster STs into clonal complex (CC) and infer evolutionary descent ([@b51-etm-0-0-3828]).

Results
=======

### Antimicrobial susceptibility of aminoglycosides

All 118 clinical strains were identified as *A. baumannii* by 16S rRNA and *recA* amplification. Among these isolates, 73 (61.86%) and 72 (61.02%) strains were resistant to gentamicin and amikacin, respectively ([Tables II](#tII-etm-0-0-3828){ref-type="table"} and [III](#tIII-etm-0-0-3828){ref-type="table"}). Thus, the resistance to amikacin and gentamicin was observed in 66 (55.93%, 66/118) *A. baumannii* isolates. A total of 78 (66.1%, 78/118) isolates were resistant to amikacin and gentamicin, and 75 (96.15%, 75/78) of the strains showed a high level of resistance (MIC, ≥256 µg/ml; [Table III](#tIII-etm-0-0-3828){ref-type="table"}).

### Co-occurrence of aminoglycoside-resistant enzymes and carbapenemases

To determine the role of the aminoglycoside-modifying enzymes in resistance and the 16S rRNA methylases, PCR was performed to detect the concomitant genes ([Table III](#tIII-etm-0-0-3828){ref-type="table"}). The positive rates of *ant(2″)-Ia*, *aac(6′)-Ib*, *aph(3′)-Ia*, *aac([@b3-etm-0-0-3828])-Ia* and *aac([@b3-etm-0-0-3828])-IIa* were 66.95 (79/118), 69.49 (82/118), 42.37 (50/118), 39.83 (47/118) and 14.41% (17/118), respectively ([Table IV](#tIV-etm-0-0-3828){ref-type="table"}). Fifty-four of 118 (45.76%) isolates harboring the 16S rRNA methyalse *armA* gene obtained high level of resistance to amikacin and gentamicin. *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtE*, *rmtF*, *rmtG* and *npmA* genes were not detected in all of the isolates.

There was a marked difference in the distribution of aminoglycoside-resistant genes among the 75 high-level aminoglycoside-resistant *A. baumannii* ([Tables III](#tIII-etm-0-0-3828){ref-type="table"} and [IV](#tIV-etm-0-0-3828){ref-type="table"}). All 54 (72.0%, 54/75) *armA*-positive strains were confirmed to serve a primary role in high level aminoglycoside resistance. However, 21 (28%, 21/75) isolates harboring aminoglycoside-modifying enzymes without the *armA* gene served the same function ([Table V](#tV-etm-0-0-3828){ref-type="table"}).

Among the 54 isolates that were *armA*-positive, the prevalence of *bla*~OXA-23~ and *bla*~OXA-51~ gene occurrences were 79.63 (43/54) and 100% (54/54), respectively. In addition, the prevalence of *ant(2″)-Ia*, *aac(6′)-Ib*, *aph(3′)-Ia*, *aac([@b3-etm-0-0-3828])-Ia*, and *aac([@b3-etm-0-0-3828])-IIa* positive rates of genes was distributed in the aminoglycoside-resistant and-susceptible strains ([Table V](#tV-etm-0-0-3828){ref-type="table"}). As described above, the present study demonstrated that aminoglycoside-modifying enzymes were mostly responsible for moderate level resistance (16 µg/ml\<MIC\<256 µg/ml) to aminoglycosides in *A. baumannii*, whereas *armA* was responsible for high-level resistance to aminoglycosides. All 75 isolates with high-level resistance to aminoglycosides harbored the carbapenemase genes *bla*~OXA-23~ (77.33%) or *bla*~OXA-51~ (100%; [Tables III](#tIII-etm-0-0-3828){ref-type="table"} and [V](#tV-etm-0-0-3828){ref-type="table"}), which (except one isolate) showed resistance to the carbapenems, imipenem and meropenem. These data suggest that the resistance to carbapenems and aminoglysides poses a threat following combination treatment of *A. baumannii* infection.

### Molecular genotyping analysis of drug-resistant isolates

To better assess the *A. baumannii* clinical population epidemiology and the genetic background of these strains, a number of molecular typing systems were applied. By comparing the ST(s) of 75 high-level aminoglycoside resistant isolates with all identified ST(s) in *A. baumannii* in the MLST database by eBUSRT analysis, 29 strains were identified that belonged to ST92, which is a globally distributed strain ([Fig. 1A](#f1-etm-0-0-3828){ref-type="fig"}). According to MLST analysis, a total of 31 different STs were assigned to the 75 high-level aminoglycoside resistant isolates, of which 21 STs were clustered into clonal complex 92 (CC92), and the remaining 10 STs were identified as singletons. The most common ST was ST92, which accounted for 38.67% (29/75) ([Fig. 1A and B](#f1-etm-0-0-3828){ref-type="fig"}). ST195, followed by ST92, presented in 5 strains, whilst ST136 and ST843 were detected in 4 strains. ST75, ST829, ST837, ST899, ST909 and ST916 were represented by 2 isolates. Molecular analysis revealed that 37 (containing 6 different STs) of the 43 isolates, which produced carbapenemase OXA-23 and 16S rRNA methylase ArmA, were grouped into CC92, while the remaining 6 isolates, which had 6 different STs, could not be clustered into any known clonal complex ([Fig. 1C](#f1-etm-0-0-3828){ref-type="fig"}). These data indicate that the prevalence of *A. baumann*ii isolates was caused by CC92 dissemination.

Discussion
==========

*A. baumannii* are important hospital-acquired pathogens that cause various types of human infections ([@b52-etm-0-0-3828]). The present study demonstrated that 75 (63.56%) strains were high-level resistant to amikacin or gentamicin, determined by susceptibility testing ([Table III](#tIII-etm-0-0-3828){ref-type="table"}), suggesting that these antibiotics can only be used for treating *A. baumannii* infections induced by susceptible strains.

As indicated above, at least one aminoglycoside resistance gene was detected in aminoglycoside-resistant *A. baumannii* strains, and different resistant genes were commonly present in the same isolates ([Tables III](#tIII-etm-0-0-3828){ref-type="table"} and [V](#tV-etm-0-0-3828){ref-type="table"}). Among these strains, the dominant aminoglycoside-resistant genotypes are *ant(2″)-Ia*, *armA* and *aac(6′)-Ib*, which were present at 66.95, 45.76 and 69.49%, respectively ([Table IV](#tIV-etm-0-0-3828){ref-type="table"}). These results indicated that the presence of *armA* and aminoglycoside-modifying enzmyes confers to the high level of aminoglycoside resistance.

The prevalence of *armA* genes in *A. baumannii* isolates has been described in several studies that showed 50% (52/104) in strains isolated in Lishui, eastern China ([@b10-etm-0-0-3828]), 60.4% (61/101) in clinical strains in Vietnam ([@b53-etm-0-0-3828]), and 59.54% (103/173) in hospitals in Beijing, China ([@b54-etm-0-0-3828]). In the present study, 45.76% (54/118, [Table IV](#tIV-etm-0-0-3828){ref-type="table"}) of isolates harbored the *armA* gene, which is similar to the above cases reported in China. In addition, it was reported that *armA* was identified in 90% (97/107) of the multidrug-resistant strains in Shanghai, eastern China ([@b55-etm-0-0-3828]). In a previous study, however, 4 (8.5%) isolates were positive for the methylase enzyme ArmA in an Algerian hospital ([@b56-etm-0-0-3828]). In conclusion, *armA* is highly prevalent worldwide, particularly in China.

The emergence of high level aminoglycoside resistance may pose a question for the combination therapy of aminoglycoside with β-lactams, particularly carbapenems in treating *A. baumannii* infections. Previously, *A. baumannii* producing OXA-23 have been increasingly described in Shanghai, eastern China ([@b38-etm-0-0-3828]). Thus, the present study identified carbapenemase genes in 75 high-level aminoglycoside resistance strains. The positive ratios of *bla*~OXA-51~ and *bla*~OXA-23~ were 100 (75/75) and 77.33% (58/75), respectively ([Table III](#tIII-etm-0-0-3828){ref-type="table"}), further demonstrating that the intrinsic OXA-51 family and the presence of OXA-23 are the most prevalent mechanisms for carbapenem resistance in *A. baumannii* ([@b57-etm-0-0-3828]). In addition, among 54 *armA*-positive isolates, the prevalence of *bla*~OXA-23~ and *bla*~OXA-51~ were 79.63 (43/54) and 100% (54/54) ([Table V](#tV-etm-0-0-3828){ref-type="table"}), which was similar to a previous study ([@b27-etm-0-0-3828],[@b56-etm-0-0-3828]). Three hospital disseminations of *A. baumannii* co-producing OXA-23 and ArmA were reported in eastern China in 2009 and 2011 ([@b21-etm-0-0-3828],[@b34-etm-0-0-3828],[@b35-etm-0-0-3828]). To the best of our knowledge, the results in the present study are the first to demonstrate the co-occurrence of carbapenemases OXA-23, OXA-51 and 16S rRNA methylase ArmA with high level aminoglycoside resistance among clinical isolates of *A. baumannii* from Chengdu, western China.

Previously, it was reported that aminoglycosides with the *aac*/*aad* riboswitch control the expression of aminoglycoside modification enzymes ([@b58-etm-0-0-3828]), indicating that bacteria can survive in an energy saving way. Therefore, these efficient modification enzymes were responsible for aminoglycoside resistance ([Table IV](#tIV-etm-0-0-3828){ref-type="table"}). In addition, it was identified that the *aac(6′)-Ib* enzyme is able to modify amikacin, even in phenotypically amikacin-susceptible isolates ([@b59-etm-0-0-3828]). Furthermore, the *aac(6′)-Ib* (69.49%) *A. baumannii* isolates were aminoglycoside-positive ([Table IV](#tIV-etm-0-0-3828){ref-type="table"}), which is different from previous studies ([@b10-etm-0-0-3828]). The reason why these differences were observed may be due to the resistance level caused by *aac(6′)-Ib*, which was regional-dependent and host bacterium-dependent ([@b59-etm-0-0-3828]).

In the present study, a higher rate of *aac([@b3-etm-0-0-3828])-IIa* (14.41%) were detected. In addition, *aac([@b3-etm-0-0-3828])-IIa* genes were detected in 47.88% of *E. coli* isolated from an Iranian hospital ([@b60-etm-0-0-3828]). Miro *et al* ([@b61-etm-0-0-3828]) found 12.4% of strains possessing *aac([@b3-etm-0-0-3828])-IIa* genes. However, there is a paucity of data regarding the *aac([@b3-etm-0-0-3828])-IIa* gene distribution in *A. baumannii*. It was reported that only 4 strains (3.7%) carried *aac([@b3-etm-0-0-3828])-IIa* genes ([@b62-etm-0-0-3828]); *aac([@b3-etm-0-0-3828])-IIa* was not identified in any strains in a study by Nowak *et al* ([@b63-etm-0-0-3828]). Previous studies have reported that *aac([@b3-etm-0-0-3828])-IIa* modifies gentamicin, which explains the observed high rate of resistance to gentamicin in these *A. baumannii* strains ([@b59-etm-0-0-3828]). The increasing prevalence of aminoglycoside resistance is partly associated with the presence of *aac(3′)-IIa*.

The PubMLST database assigned *A. baumannii* strains to 920 different types. ST92, a globally distributed type, was the predicted founder of CC92 in the *A. baumannii* MLST database. CC92 is the largest and most geographically diverse clonal complex ([@b64-etm-0-0-3828]). Combined ST profiles from MLST and eBURST analyses showed that almost all isolates were clonally related and CC92 was responsible for the spread of disease ([Fig. 1](#f1-etm-0-0-3828){ref-type="fig"}). The present study further suggests the possibility that *A. baumannii* carrying *bla*~OXA-23~ and *armA* genes contribute towards CC92 dissemination. In addition, the present study described the emergence and spread of a clonal strain of the high-level aminoglycoside-resistant *A. baumannii*. These findings support the hypothesis that certain restricted genetic backgrounds serve an important role in the emergence of aminoglycoside resistance, since some genetic backgrounds may be prone to acquire a foreign resistance gene and maintain its stability and expression ([@b46-etm-0-0-3828]). Further analysis of the epidemiology of *A. baumannii* is required in order to determine the prevalence of drug-resistant genes.

In conclusion, the present study demonstrated that 16S rRNA methylase ArmA and modifying enzyme occurrence confer high level resistance to aminoglycoside in *A. baumannii*. In addition, it was identified that the high level aminoglycoside resistance of *A. baumannii* strains, harboring high percentages of positive carbapenemases *bla*~OXA-23~ and *bla*~OXA-51~, strongly suggest that a better understanding of the global epidemiology and monitoring for the presence of resistance genes is urgently required.
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###### 

Primers used in the present study for polymerase chain reaction detection.

  Primer                 Target         Oligonucletides (5′ to 3′)   Expected size (bp)
  ---------------------- -------------- ---------------------------- --------------------
  *armA* forward         *armA*         AGGTTGTTTCCATTTCTGAG         591
  *armA*-R                              TCTCTTCCATTCCCTTCTCC         
  *rmtA* forward         *rmtA*         CTAGCGTCCATCCTTTCCTC         635
  *rmtA*-R                              TTTGCTTCCATGCCCTTGCC         
  *rmtB* forward         *rmtB-*        CCCAAACAGACCGTAGAGGC         585
  *rmtB*-R                              CTCAAACTCGGCGGGCAAGC         
  *rmtC* forward         *rmtC*         CGAAGAAGTAACAGCCAAAG         711
  *rmtC*-R                              ATCCCAACATCTCTCCCACT         
  *rmtD* forward         *rmtD*         CGGCACGCGATTGGGAAGC          401
  *rmtD*-R                              CGGAAACGATGCGACGAT           
  *rmtE* forward         *rmtE*         ATGAATATTGATGAAATGGTTGC      823
  *rmtE*-R                              TGATTGATTTCCTCCGTTTTTG       
  *rmtF* forward         *rmtF*         GCGATACAGAAAACCGAAGG         589
  *rmtF*-R                              ACCAGTCGGCATAGTGCTTT         
  *rmtG* forward         *rmtG*         AAATACCGCGATGTGTGTCC         250
  *rmtG* reverse                        ACACGGCATCTGTTTCTTCC         
  *rmtH* forward         *rmtH*         GCTTAAACCCGCTGATGCT          332
  *rmtH* reverse                        AAACCAGGTGGCGTAGTGC          
  *npmA* forward         *npmA*         GGAGGGCTATCTAATGTGGT         371
  *npmA* reverse                        GCCCAAAGAGAATTAAACTG         
  *ant(2″)-Ia* forward   *ant(2″)-Ia*   GCTTACGTTGTCCCGCATTT         215
  *ant(2″)-Ia* reverse                  CCTTGGTGATCTCGCCTTTC         
  *aph(3′)-Ia* forward   *aph(3′)-Ia*   CGAGCATCAAATGAAACTGC         623
  *aph(3′)-Ia* reverse                  GCGTTGCCAATGATGTTACAG        
  *aac(3)-Ia* forward    *aac(3)-Ia*    GACATAAGCCTGTTCGGTT          372
  *aac(3)-Ia* reverse                   CTCCGAACTCACGACCGA           
  *aac(3)-IIa* forward   *aac(3)-IIa*   ATGCATACGCGGAAGGC            822
  *aac(3)-IIa* reverse                  TGCTGGCACGATCGGAG            
  *aac(6′)-Ib* forward   *aac(6′)-Ib*   AAGCGTTTTAGCGCAAGAGT         366
  *aac(6′)-Ib* reverse                  GCGTGTTTGAACCATGTACA         
  *OXA-23* forward       *OXA-23*       GATCGGATTGGAGAACCAGA         501
  *OXA-23* reverse                      ATTTCTGACCGCATTTCCAT         
  *OXA-24* forward       *OXA-24*       CAAGAGCTTGCAAGACGGACT        420
  *OXA-24* reverse                      TCCAAGATTTTCTAGCRACTTATA     
  *OXA-51* forward       *OXA-51*       TAATGCTTTGATCGGCCTTG         353
  *OXA-51* reverse                      TGGATTGCACTTCATCTTGG         
  *OXA-58* forward       *OXA-58*       TCGATCAGAATGTTCAAGCGC        530
  *OXA-58* reverse                      ACGATTCTCCCCTCTGCGC          
  *NDM-1* forward        *NDM-1*        TCTCGACATGCCGGGTTTCGG        475
  *NDM-1* reverse                       ACCGAGATTGCCGAGCGACTT        
  *KPC* forward          *KPC*          GCTCAGGCGCAACTGTAAGT         823
  *KPC* reverse                         GTCCAGACGGAACGTGGTAT         
  *IMP* forward          *IMP*          CTACCGCAGAGTCTTTG            587
  *IMP* reverse                         AACCAGTTTTGCCTTACCAT         
  *SIM* forward          *SIM*          TACAAGGGATTCGGCATCG          570
  *SIM* reverse                         TAATGGCCTGTTCCCATGTG         

###### 

Susceptibilities to two types of aminoglycosides of *A. baumannii* isolates.

  Drug name    Resistant isolates, n (%)   Intermediate isolates, n (%)   Sensitive isolates, n (%)   Total, n (%)
  ------------ --------------------------- ------------------------------ --------------------------- --------------
  Gentamicin   73 (61.86)                  3 (2.54)                       42 (35.60)                  118 (100)
  Amikacin     72 (61.02)                  0 (0.00)                       46 (38.98)                  118 (100)

###### 

Molecular resistance characteristics of 75 high level aminoglycoside resistance isolates.

        Susceptibility patter (MIC in µg/ml)   Resistance genes                                           
  ----- -------------------------------------- ------------------ ----- ----- --- --- --- --- --- --- --- ---
  001   \>1024                                 1024               16    32    1   1   1   1   0   0   1   1
  003   256                                    1024               16    32    1   1   1   1   0   0   1   1
  005   \>1024                                 1024               32    64    1   1   1   1   0   0   1   1
  006   \>1024                                 1024               32    64    0   1   1   1   0   0   1   1
  007   \>1024                                 1024               32    64    1   1   1   1   1   0   1   1
  008   \>1024                                 1024               32    64    1   1   1   0   1   0   0   1
  011   \>1024                                 1024               16    32    1   1   1   1   0   0   1   1
  013   256                                    256                8     16    1   1   1   1   1   0   1   1
  016   \>1024                                 1024               16    32    0   1   1   1   0   0   1   1
  018   256                                    256                8     16    1   0   1   0   1   0   1   1
  020   2                                      256                8     16    1   1   1   1   0   0   0   1
  026   \>1024                                 1024               16    32    1   1   0   1   0   0   1   1
  027   \>1024                                 1024               16    32    1   1   1   0   1   0   1   1
  028   1024                                   1024               8     16    1   1   1   0   1   0   0   1
  030   \>1024                                 1024               32    32    0   0   1   0   1   0   0   1
  031   \>1024                                 1024               32    16    0   1   0   1   1   0   0   1
  034   \>1024                                 1024               32    64    1   1   1   1   1   0   1   1
  035   \>1024                                 4                  32    64    1   1   1   0   1   0   0   1
  036   \>1024                                 1024               16    32    1   1   0   0   0   0   1   1
  037   \>1024                                 1024               32    64    1   1   1   0   1   0   1   1
  039   \>1024                                 1024               32    64    1   1   1   1   1   0   0   1
  040   \>1024                                 1024               32    32    1   1   1   1   1   0   0   1
  041   \>1024                                 1024               32    64    1   1   1   0   1   0   1   1
  042   \>1024                                 512                32    64    1   1   1   1   0   0   1   1
  043   \>1024                                 1024               32    64    1   1   1   1   1   0   1   1
  044   \>1024                                 1024               64    128   1   1   1   0   1   0   1   1
  046   \>1024                                 1024               32    64    1   1   0   0   0   0   1   1
  047   \>1024                                 1024               64    64    1   0   1   0   0   1   1   1
  048   \>1024                                 1024               32    64    0   1   1   1   0   1   0   1
  049   \>1024                                 512                32    64    0   1   1   1   0   0   1   1
  050   \>1024                                 512                32    32    1   1   1   0   1   1   1   1
  051   \>1024                                 1024               32    32    1   1   1   0   0   1   1   1
  052   \>1024                                 1024               64    128   1   0   1   0   0   1   1   1
  053   \>1024                                 512                32    32    0   1   1   1   1   1   1   1
  054   \>1024                                 512                32    32    1   1   1   0   1   0   1   1
  057   \>1024                                 1024               32    64    0   1   1   1   1   0   1   1
  058   \>1024                                 1024               32    64    1   0   1   0   1   0   1   1
  059   \>1024                                 512                32    32    1   1   1   0   1   0   1   1
  060   \>1024                                 1024               32    32    1   1   1   0   1   0   1   1
  061   \>1024                                 1024               16    32    1   0   1   0   0   0   1   1
  062   \>1024                                 512                32    32    1   0   1   0   1   0   1   1
  063   \>1024                                 1024               32    32    0   1   1   0   1   0   1   1
  064   512                                    8                  32    32    1   1   1   0   1   0   1   1
  065   256                                    8                  32    16    1   1   1   1   0   0   1   1
  066   \>1024                                 512                32    64    1   1   1   1   1   0   1   1
  067   256                                    256                16    32    1   1   1   1   0   0   1   1
  068   \>1024                                 512                32    32    1   1   1   1   0   0   1   1
  069   \>1024                                 512                32    32    1   1   1   1   1   0   1   1
  072   256                                    256                16    16    1   1   1   0   1   0   1   1
  074   512                                    2                  16    8     0   1   1   0   0   0   1   1
  075   8                                      1024               32    32    0   1   0   1   0   0   1   1
  076   \>1024                                 \>1024             64    64    1   1   0   1   0   0   1   1
  079   512                                    512                32    64    0   1   0   0   0   1   1   1
  080   512                                    512                64    128   0   1   1   0   0   1   1   1
  082   512                                    512                32    32    0   1   1   0   0   0   1   1
  085   \>1024                                 512                16    32    1   1   1   1   1   1   0   1
  087   512                                    512                32    32    1   1   1   0   0   1   0   1
  089   4                                      512                16    32    1   1   1   1   1   1   0   1
  090   \>1024                                 1024               32    32    1   1   1   1   0   1   0   1
  093   \>1024                                 1024               32    128   0   1   1   1   1   0   0   1
  094   \>1024                                 \>1024             16    32    1   1   1   1   1   1   0   1
  095   512                                    512                16    32    1   1   0   1   0   1   1   1
  096   \>1024                                 \>1024             32    32    1   1   1   1   1   0   1   1
  097   \>1024                                 \>1024             16    32    1   1   1   1   1   0   1   1
  098   512                                    512                16    32    0   0   1   0   0   1   1   1
  099   512                                    256                32    32    0   0   1   1   1   1   1   0
  100   8                                      512                0.5   1     0   0   0   0   1   0   0   1
  101   \>1024                                 512                32    32    0   1   1   1   0   0   1   1
  102   512                                    256                32    32    1   1   1   0   0   0   1   1
  104   512                                    256                32    32    1   1   1   1   1   0   1   1
  106   1024                                   512                32    32    0   1   1   1   0   1   1   1
  107   512                                    256                16    32    1   1   1   0   0   0   1   1
  109   \>1024                                 512                8     16    1   1   1   0   0   0   1   1
  113   \>1024                                 1024               8     0.5   0   0   0   0   0   0   0   1
  120   \>1024                                 2                  8     32    1   1   1   0   0   0   1   1

MIC, minimum inhibitory concentration.

###### 

Positive rates of genes in *A. baumannii*.

  Gene           Positive rate, % (n/118)   Gene           Positive rate, % (n/118)
  -------------- -------------------------- -------------- --------------------------
  *armA*         45.76 (54/118)             *aph(3′)-Ia*   42.37 (50/118)
  *aac(6′)-Ib*   69.45 (82/118)             *aac(3)-Ia*    39.83 (47/118)
  *ant(2″)-la*   66.95 (79/118)             *aac(3)-IIa*   14.41 (17/118)

###### 

Distribution of aminoglycoside resistance genes in 75 high level aminoglycoside resistance clinical isolates of *A. baumannii*, expressed as positive (+) or negative (−).

  *armA*-positive aminoglycoside resistance gene profile (n=54)   *bla*~OXA-23~ (n=58)   *bla*~OXA-51~ (n=75)   No. of isolates
  --------------------------------------------------------------- ---------------------- ---------------------- -----------------
  *ant(2″)-Ia*                                                    +2                     \+                     2 (2.67%)
  *aac(6)-Ib*                                                     +1                     \+                     1 (1.33%)
  *ant(2)-Ia+aac(6′)-Ib*                                          +4                     \+                     4 (5.33%)
  *ant(2)-Ia+aph(3′)-Ia*                                          +2                     \+                     2 (2.67%)
  *aac(6′)-Ib+aac(3)-Ia*                                          +3                     \+                     3 (4.0%)
  *aac(6′)-Ib+aac(3)-IIa*                                         +2                     \+                     2 (2.67%)
  *ant(2″)-Ia+aac(6′)-Ib+aac(3)-Ia*                                 +9/−3                \+                     12 (16%)
  *ant(2″)-Ia+aac(6′)-Ib+aac(3)-IIa*                              +1/−1                  \+                     2 (2.67%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia*                              +9/−1                  \+                     10 (13.3%)
  *ant(2″)-Ia+aph(3′)-Ia+aac(3)-IIa*                              +1                     \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia+aac(3)-Ia*                    +8/−2                  \+                     10 (13.3%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia+aac(3)-IIa*                   −1                     \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aac(3)-Ia+aac(3)-IIa*                    +1                     \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia+aac(3)-Ia+aac(3)-IIa*         −3                     \+                     3 (4.0%)
  None of *armA genes* (21)                                                                                     
  *ant(2″)-Ia*                                                    \+                     \+                     1 (1.33%)
  *aac(6′)-Ib*                                                    −                      \+                     1 (1.33%)
  *aac(6′)-Ib+ant(2″)-Ia*                                         \+                     \+                     1 (1.33%)
  *aac(6′)-Ib+aac(3)-Ia*                                          −2                     \+                     2 (2.67%)
  *aac(6′)-Ib+aac(3)-IIa*                                         \+                     \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia*                              +5                     \+                     5 (6.67%)
  *ant(2″)-Ia+aac(6′)-Ib+aac(3)-Ia*                               \+                     \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aac(3)-IIa*                              +2                     \+                     2 (2.67%)
  *ant(2″)-Ia+aph(3′)-Ia+aac(3)-IIa*                              −                      \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia+aac(3)-Ia*                    +/−2                   \+                     3 (4.0%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia+aac(3)-IIa*                   \+                     \+                     1 (1.33%)
  *aac(6′)-Ib+aph(3′)-Ia+aac(3)-Ia+aac(3)-IIa*                    \+                     \+                     1 (1.33%)
  *ant(2″)-Ia+aac(6′)-Ib+aph(3′)-Ia+aac(3)-Ia+aac(3)-IIa*         \+                     \+                     1 (1.33%)

[^1]: Contributed equally
